These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 619937)

  • 21. Relationship between lipid composition and drug metabolizing capacity of human liver.
    Savolainen MJ; Arranto AJ; Hassinen IE; Luoma PV; Pelkonen RO; Sotaniemi EA
    Eur J Clin Pharmacol; 1985; 27(6):727-32. PubMed ID: 3987778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma high-density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatment.
    Luoma PV; Sotaniemi EA; Pelkonen RO; Myllylä VV
    Scand J Clin Lab Invest; 1980 Apr; 40(2):163-7. PubMed ID: 7256184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vivo activity of drug-metabolizing enzymes in various pathological conditions].
    Krakovskiĭ ME; Ashirmetov AKh
    Vopr Med Khim; 1985; 31(1):76-9. PubMed ID: 3984279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species.
    McManus ME; Ilett KF
    Xenobiotica; 1979 Feb; 9(2):107-18. PubMed ID: 433309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in drug metabolism in workers exposed to polychlorinated biphenyls.
    Alvares AP; Fischbein A; Anderson KE; Kappas A
    Clin Pharmacol Ther; 1977 Aug; 22(2):140-6. PubMed ID: 407043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.
    Carcillo JA; Doughty L; Kofos D; Frye RF; Kaplan SS; Sasser H; Burckart GJ
    Intensive Care Med; 2003 Jun; 29(6):980-984. PubMed ID: 12698250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cigarette smoking and drug metabolism.
    Vähäkangas K; Pelkonen O; Sotaniemi E
    Clin Pharmacol Ther; 1983 Mar; 33(3):375-80. PubMed ID: 6825392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of urea on hexobarbital and antipyrine disposition in rats.
    Valentovic M; Bachmann K
    Pharmacology; 1980; 21(3):167-74. PubMed ID: 7413718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipyrine half-life and drug elimination.
    Breckenridge A
    Clin Pharmacokinet; 1980; 5(3):201-3. PubMed ID: 7389234
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of combined pre-treatment on the metabolism of antipyrine in the rat.
    Szabó I; Renczes G; Gachályi B
    Acta Physiol Hung; 1995; 83(1):51-3. PubMed ID: 7660837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer and nutrition (review).
    McLean AE
    Nahrung; 1976; 20(4):339-42. PubMed ID: 781541
    [No Abstract]   [Full Text] [Related]  

  • 35. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy.
    Chiba K; Ishizaki T; Tabuchi T; Wagatsuma T; Nakazawa Y
    Obstet Gynecol; 1982 Nov; 60(5):620-6. PubMed ID: 6815599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiopyrine half-life as a measure of hepatic enzyme induction: clinical applications in a chronic epileptic population.
    Byrne E; Harman AW; Frewin DB; Hallpike JF
    Clin Exp Neurol; 1979; 16():183-9. PubMed ID: 550940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranitidine alters antipyrine metabolism in control and phenobarbital-treated mice.
    Espiritu-Quiza MF; Skinner MH; Blaschke TF
    Methods Find Exp Clin Pharmacol; 1990 Nov; 12(9):631-6. PubMed ID: 2084458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative metabolism of benzo[a]pyrene and drugs in human liver.
    Kapitulnik J; Popper PJ; Conney AH
    Clin Pharmacol Ther; 1977 Feb; 21(2):166-76. PubMed ID: 837635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.
    Sotaniemi EA; Pelkonen RO; Puukka M
    Eur J Clin Pharmacol; 1980 Apr; 17(4):267-74. PubMed ID: 6105079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.